Rabbit Recombinant Monoclonal GPCR GPR18 antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Not recommended | Not recommended | Tested | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Predicted | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Predicted | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/5000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Receptor for endocannabinoid N-arachidonyl glycine (NAGly) (PubMed:16844083, PubMed:24762058, PubMed:27572937). However, conflicting results about the role of NAGly as an agonist are reported (PubMed:27018161). Can also be activated by plant-derived and synthetic cannabinoid agonists (PubMed:24762058). The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase (PubMed:16844083). May contribute to regulation of the immune system. Is required for normal homeostasis of CD8+ subsets of intraepithelial lymphocytes (IELs) (CD8alphaalpha and CD8alphabeta IELs)in small intstine by supporting preferential migration of CD8alphaalpha T-cells to intraepithelial compartment over lamina propria compartment, and by mediating their reconstitution into small intestine after bone marrow transplant (By similarity). Plays a role in hypotensive responses, mediating reduction in intraocular and blood pressure (By similarity). Mediates NAGly-induced process of reorganization of actin filaments and induction of acrosomal exocytosis (PubMed:27572937).
GPCRW, GPR18, N-arachidonyl glycine receptor, NAGly receptor, G-protein coupled receptor 18
Rabbit Recombinant Monoclonal GPCR GPR18 antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
GPR18 also known as N-arachidonyl glycine receptor is a G protein-coupled receptor (GPCR) found in various human tissues. It has an approximate mass of 40 kDa. This receptor is expressed most notably in immune cells including lymphocytes and macrophages as well as in the spleen and thymus. In addition to immune tissues GPR18 is also present in the heart brain and gastrointestinal system.
This receptor plays a role in cellular signaling as part of the cardiovascular and immune system regulation. GPR18 binds specific ligands such as N-arachidonoyl glycine facilitating intracellular communication and response to environmental changes. It does not function alone but integrates into GPCR complexes acting in concert with other receptors to regulate physiological functions like inflammation and cell migration.
The involvement of GPR18 in the endocannabinoid signaling and in the immune system makes it an essential player. It interfaces significantly with the endocannabinoid system influencing pathways like the calcium signaling pathway and possibly the MAPK signaling pathway. GPR18 interacts with proteins such as CB2 (cannabinoid receptor 2) to modulate immune responses inflammation and other critical cellular processes.
GPR18 is associated with conditions like inflammation and cardiovascular diseases. Changes in its expression or function can contribute to the development of these health issues. The receptor's interaction with proteins like CB2 becomes evident in these contexts where it may modulate disease progression and provide potential therapeutic targets for treating inflammation-related disorders or heart diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-GPCR GPR18 antibody [EPR12359] (ab174835) at 1/1000 dilution
Lane 1: HuT-78 cell lysate at 10 µg
Lane 2: 293T cell lysate at 10 µg
All lanes: Goat anti-rabbit HRP at 1/2000 dilution
Developed using the ECL technique.
Predicted band size: 38 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com